THERAPY DOSSIER · th-0591fd85c476

LP-211 (N-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide)

Drug · ChEMBL compound_search for 'LP-211' returned 0 records (explicit negative result, not an omission). LP-211 is a research-grade selective 5-HT7 receptor agonist with no INN/USAN name and no ChEMBL entity. ClinicalTrials.gov searched for 'LP-211 OR 5-HT7 receptor agonist': 0 hits. No human trial administers LP-211 or any selective 5-HT7 agonist.

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: ChEMBL compound_search for 'LP-211' returned 0 records (explicit negative result, not an omission). LP-211 is a research-grade selective 5-HT7 receptor agonist with no INN/USAN name and no ChEMBL entity. ClinicalTrials.gov searched for 'LP-211 OR 5-HT7 receptor agonist': 0 hits. No human trial administers LP-211 or any selective 5-HT7 agonist.
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26369408 ↗2015Reported harm

Serotonin 5-HT7 receptor agonist, LP-211, exacerbates Na(+), K(+)-ATPase/Mg(2+)-ATPase imbalances in spinal cord-injured male rats.

RatSpinal cord injuryCompressionWistar albinoMalen = 60 rats in total, six groups of tenIntraperitoneal0.003 to 0.3 mg/kgCommenced two weeks after spinal cord injury

Model: Extradural aneurysm clip compression of the spinal cord at T10 (Yasargil FE 760 clip, 180 g closing force, 1 min) after T9-T11 laminectomy

LP-211 lowered serum sodium and raised serum potassium and magnesium in spinal cord-injured rats, producing hyponatraemia, hyperkalaemia and hypermagnesaemia. The authors concluded LP-211 may not be a potential electroprotective agent for spinal cord injury.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…

LP-211 (N-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide)